i-Base home
Search Menu
  • Home
  • HTB
  • Conference reports
  • 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Februrary 24-28 2002

HTB

9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Februrary 24-28 2002

10 April 2002. Related: Conference reports, Conference index, CROI 9 (Retrovirus) 2002.

Reports from the conference.

  • Study results shed light on cardiovascular risks: role of antiretrovirals and metabolism of lipids and sugars
  • Switch to abacavir improves lipoatrophy
  • Potential use of niacin to reduce intra-abdominal fat
  • Further benefits shown with New-Fill for facial atrophy
  • Lipodystrophy associated with lower CD4+ T cell counts
  • Treatment interruptions
  • Analysis of cells from long term non-progressors points the way to using vaccines and STIs to restore immune response to HIV
  • Symposium on T cell turnover and thymic function
  • New drugs: perhaps some genuine excitement this time
  • T20 and beyond: inhibition of HIV attachment and fusion at the 9th CROI
  • Pharmacogenetics predict abacavir hypersensitivity
  • Pregnancy: growing body of evidence supports treating maternal disease
  • Peripheral neuropathy update

Links to other websites are current at date of posting but not maintained.

  • HTB RSS
  • Study results shed light on cardiovascular risks: role of antiretrovirals and metabolism of lipids and sugars
  • South Africa finds 1 billion Rand to treble HIV budget, after Mandela confronts Mbeki

Early access

  • Single undetectable viral load is sufficient for U=U in the context of good adherence 23 January 2021
  • US FDA approves long-acting injectable HIV treatment: monthly dosing 22 January 2021
  • Latest update on HIV and COVID-19 from BHIVA and EACS (January 2021) 15 January 2021
  • Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study       14 January 2021
  • All early access reports

Current issues

  • January 2021
  • December 2020
  • November 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook